170 related articles for article (PubMed ID: 32874056)
1. Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer.
Bian LF; Zhao XH; Gao BL; Zhang S; Ge GM; Zhan DD; Ye TT; Zheng Y
World J Gastroenterol; 2020 Aug; 26(30):4442-4452. PubMed ID: 32874056
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of abdominal pain after transarterial chemoembolization of hepatocellular carcinoma: a single-center retrospective study.
Du QQ; Liang M; Jiang B; Zhang M; Yu XL; Li X; Hao JH
Eur J Oncol Nurs; 2023 Oct; 66():102355. PubMed ID: 37524027
[TBL] [Abstract][Full Text] [Related]
3. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma.
Khalaf MH; Sundaram V; AbdelRazek Mohammed MA; Shah R; Khosla A; Jackson K; Desai M; Kothary N
Radiology; 2019 Jan; 290(1):254-261. PubMed ID: 30299233
[TBL] [Abstract][Full Text] [Related]
4. Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.
Yang Y; Chen S; Yan Z; Jiao Y; Yan X; Li Y
Comput Math Methods Med; 2022; 2022():5203166. PubMed ID: 35941895
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma.
Pachev A; Raynaud L; Paulatto L; Dioguardi Burgio M; Roche V; Garcia Alba C; Sibert A; Lagadec M; Kavafyan-Lasserre J; Paugam-Burtz C; Vilgrain V; Ronot M
Eur Radiol; 2021 May; 31(5):3267-3275. PubMed ID: 33123789
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
[TBL] [Abstract][Full Text] [Related]
7. Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis.
Roehlen N; Stoehr F; Müller L; Luxenburger H; Gairing SJ; Reincke M; Schultheiss M; Berisha F; Weinmann A; Foerster F; Marquardt JU; Thimme R; Galle PR; Bettinger D; Kloeckner R
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37756031
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
9. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
10. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
11. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
[TBL] [Abstract][Full Text] [Related]
12. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
14. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
15. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
16. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
[TBL] [Abstract][Full Text] [Related]
17. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres
Peng Z; Cao G; Hou Q; Li L; Ying S; Sun J; Zhou G; Zhou J; Zhang X; Ji W; Yu Z; Li T; Zhu D; Hu W; Ji J; Du H; Shi C; Guo X; Fang J; Han J; Gu W; Xie X; Sun Z; Xu H; Wu X; Hu T; Huang J; Hu H; Zheng J; Luo J; Chen Y; Yu W; Shao G
Oncol Res; 2020 May; 28(3):249-271. PubMed ID: 31856933
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
Boulin M; Adam H; Guiu B; Aho LS; Cercueil JP; Di Martino C; Fagnoni P; Minello A; Jouve JL; Hillon P; Bedenne L; Lepage C
Dig Liver Dis; 2014 Apr; 46(4):358-62. PubMed ID: 24462550
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment.
Lima M; Dutra S; Gomes FV; Bilhim T; Coimbra É
Acta Med Port; 2018 Jan; 31(1):22-29. PubMed ID: 29573765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
